Subscribe
The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.
Treating Waldenstrom’s Macroglobulinemia
Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years
Drug Duo Granted Priority Review to Treat Waldenstrom Macroglobulinemia
259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512
609-716-7777
